Compare Stocks → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADROOTCMKTS:HBPCFNASDAQ:OASMNASDAQ:ORMPNASDAQ:TFFP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADROAduro Biotech$10.93$4.51▼$20.20$236.61M0.4162,237 shs171,500 shsHBPCFHelix BioPharma$0.14$0.14$0.14▼$0.15$29.84M-0.11,544 shsN/AOASMOasmia Pharmaceutical AB (publ)$0.02$1.46$0.94▼$5.70$1.50M0.9698,414 shs250 shsORMPOramed Pharmaceuticals$2.82+3.7%$2.90$1.67▼$5.25$110.21M1.83143,840 shs160,213 shsTFFPTFF Pharmaceuticals$6.59+1.5%$6.66$4.55▼$21.25$15.35M1.2944,399 shs37,657 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADROAduro Biotech0.00%0.00%0.00%0.00%0.00%HBPCFHelix BioPharma0.00%-6.96%-5.03%-5.03%-5.68%OASMOasmia Pharmaceutical AB (publ)0.00%0.00%0.00%0.00%-60.00%ORMPOramed Pharmaceuticals+3.68%-4.73%-20.56%+20.51%+29.95%TFFPTFF Pharmaceuticals+1.54%-17.11%+14.41%-11.78%-61.24%Trump’s “Tax Free” Retirement Strategy (Ad)Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADROAduro BiotechN/AN/AN/AN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ATFFPTFF Pharmaceuticals0.7937 of 5 stars2.03.00.00.02.30.01.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADROAduro BiotechN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/A$100.001,417.45% UpsideSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADROAduro Biotech$17.26M0.00N/AN/A$4.07 per share0.00HBPCFHelix BioPharmaN/AN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)$220K6.82N/AN/A$0.63 per share0.03ORMPOramed Pharmaceuticals$1.34M85.27N/AN/A$4.04 per share0.70TFFPTFF Pharmaceuticals$500K31.24N/AN/A$16.44 per share0.40Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADROAduro Biotech-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/AHBPCFHelix BioPharma-$4.69M-$0.04N/A∞N/AN/A-817.64%-308.71%6/12/2024 (Estimated)OASMOasmia Pharmaceutical AB (publ)-$18.95MN/A0.00∞N/A-8,633.64%-43.94%-28.92%N/AORMPOramed Pharmaceuticals$5.53M$0.1420.14∞N/A-747.02%-7.15%-5.70%5/9/2024 (Estimated)TFFPTFF Pharmaceuticals-$31.77MN/A0.00N/AN/A-2,559.40%-145.90%-134.79%4/2/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADROAduro BiotechN/AN/AN/AN/AN/AHBPCFHelix BioPharmaN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/ATFFPTFF PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADROAduro BiotechN/A8.918.91HBPCFHelix BioPharmaN/A1.461.46OASMOasmia Pharmaceutical AB (publ)N/A0.800.73ORMPOramed PharmaceuticalsN/A3.063.06TFFPTFF PharmaceuticalsN/A9.549.54OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADROAduro Biotech49.93%HBPCFHelix BioPharmaN/AOASMOasmia Pharmaceutical AB (publ)0.11%ORMPOramed Pharmaceuticals12.73%TFFPTFF Pharmaceuticals15.25%Insider OwnershipCompanyInsider OwnershipADROAduro Biotech5.90%HBPCFHelix BioPharma7.60%OASMOasmia Pharmaceutical AB (publ)N/AORMPOramed Pharmaceuticals12.00%TFFPTFF Pharmaceuticals5.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADROAduro Biotech15216.21 millionN/AOptionableHBPCFHelix BioPharma9216.67 million200.21 millionNot OptionableOASMOasmia Pharmaceutical AB (publ)5774.97 millionN/ANot OptionableORMPOramed Pharmaceuticals1240.52 million35.66 millionOptionableTFFPTFF Pharmaceuticals152.37 million2.23 millionOptionableADRO, HBPCF, TFFP, ORMP, and OASM HeadlinesSourceHeadlineTFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programsglobenewswire.com - March 27 at 4:01 PMTFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meetingglobenewswire.com - March 25 at 9:01 AMTFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesglobenewswire.com - March 22 at 3:11 PMTFF Pharmaceuticals, Inc. (TFFP)finance.yahoo.com - March 21 at 9:12 PMTFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rulesglobenewswire.com - March 20 at 12:00 PMTFF Pharmaceuticals Announces Update on Clinical Programsglobenewswire.com - March 20 at 9:03 AMTFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024globenewswire.com - March 14 at 4:47 PMTff Pharmaceuticals Inc (TFFP)uk.investing.com - March 12 at 6:49 PMTFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis Conferencefinance.yahoo.com - January 24 at 10:43 AMTFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 Meetingfinance.yahoo.com - January 9 at 10:39 AMTFF Pharmaceuticals Inc Ordinary Sharesmorningstar.com - January 5 at 1:08 PMPositive Phase II Results Bolster Buy Rating for TFF Pharmaceuticals with Raised Price Targetmarkets.businessinsider.com - December 21 at 8:22 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q3 2023investorplace.com - December 20 at 11:12 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2023investorplace.com - December 20 at 11:12 AMTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Misses Revenue for Q1 2023investorplace.com - December 20 at 11:12 AMTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TACfinanznachrichten.de - December 19 at 8:56 AMTFF Pharma Reveals Positive Initial Data From Ongoing Phase 2 Trials Of TFF VORI And TFF TACmarkets.businessinsider.com - December 19 at 8:56 AMTFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TACfinance.yahoo.com - December 19 at 8:56 AMTFF Pharmaceuticals to Host Webcast and Conference to Review Initial Data from the Ongoing Phase 2 Trials of TFF VORI and TFF TACfinance.yahoo.com - December 18 at 5:44 PMTFF Declares Reverse Stock Split For 1 Post-split Share For Every 25 Pre-split Sharesmarkets.businessinsider.com - December 15 at 4:02 PMTFF Pharmaceuticals Announces Reverse Stock Splitfinance.yahoo.com - December 15 at 10:39 AMTFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directorsfinance.yahoo.com - November 30 at 9:05 AMTFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023finance.yahoo.com - November 27 at 8:51 AMTFF Pharmaceuticals Inc Ordinary Shares TFFPmorningstar.com - November 23 at 1:33 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAduro BiotechNASDAQ:ADROChinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.Helix BioPharmaOTCMKTS:HBPCFHelix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company is headquartered in Toronto, Canada.Oasmia Pharmaceutical AB (publ)NASDAQ:OASMOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.Oramed PharmaceuticalsNASDAQ:ORMPOramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.TFF PharmaceuticalsNASDAQ:TFFPTFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as Augmenta monoclonal antibodies for the treatment of COVID-19 therapeutics; TFF Niclosamide, which is completed Phase 1 clinical trials for the treatment of COVID-19 disease; and other vaccines. TFF Pharmaceuticals, Inc. has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop Augmenta monoclonal antibodies; a licensing and collaboration agreement with UNION therapeutics A/S; and a collaborative research and development agreement with the National Institute of Environmental Health Sciences to develop dry powder formulations of hyaluronan to prevent and treat respiratory diseases. The company was incorporated in 2018 and is headquartered in Fort Worth, Texas. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.